Description

CD21 is a 145 kD transmembrane protein also known as complement C3d receptor (C3dR), complement receptor 2 (CR2), and Epstein-Barr virus receptor. CD21 is expressed on B cells, follicular dendritic cells, subsets of normal thymocytes and T cells, and some epithelial cells. CD21 is the receptor used by Epstein-Barr virus to infect B cells and is also the complement receptor for C3d. CD21 has also been shown to interact with a number of proteins, including CD23, CD19, annexin VI, CD81, iC3b, complement receptor 1 (CR1, CD35), and interferon-α 1 (IFN-α1).

Formulation

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Björck P, et al. 1993. Eur. J. Immunol. 23:1771.
2. Frémeaux-Bacchi V, et al. 1996. Eur. J. Immunol. 26:1497.
3. Ling NR, et al. 1995. Clin. Exp. Immunol. 101:369.
4. Wang, C, et al. 2011. BMC Immunol. 12:53. (IHC)